

PATIENT INFORMATION

Patient Name: _____ DOB: _____ Phone: _____ Sex: M F Ht: _____ Wt: _____ lbs kg

Primary Language: _____ Allergies: _____

Patient Preferred Location: _____

<ICD 10 CODE REQUIRED>

DIAGNOSIS & CLINICAL INFORMATION**ICD 10 Code**

J45.51 Severe Persistent Asthma, w/Acute Exacerbation

J45.50 Severe Persistent Asthma, Uncomplicated

Other: _____

REQUIRED: Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.
LAB RESULTS: Blood eosinophil level OR CBC with differential AND pulmonary function test prior to initiating therapy.

PRESCRIPTION**FASENRA (benralizumab)****Loading Dose**

SubQ: Inject 30 mg every 4 weeks for the first 3 doses

Maintenance Dose

SubQ: Inject 30 mg every 8 weeks for one year

Is the patient on any other disease modifying therapy? Yes No

If yes, please note therapy and last dose: _____

Post Treatment Observations: The patient is observed for 30 minutes following the first administration.**Adverse Events:** In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.**Comments:**_____

_____**PRESCRIBER INFORMATION**

Prescriber Name: _____ Signature: _____

Date: _____ NPI #: _____ Specialty: _____

Supervising Physician: _____ (If Applicable)

Address: _____ City: _____ State: _____ Zip: _____

Contact Name: _____ Phone: _____ Fax: _____ Email: _____